•  
  •  
  •  
  •  

2026-08-11 17:33:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Lemon Tree Hotels signs Second hotel in Mcleodganj
  • Axis Mutual Fund launches Axis Nifty Energy Index Fund & Axis Nifty Energy ETF NFOs offering exposure to India's evolving capital energy ecosystem
  • Websol Energy Q1FY27 Revenue up 70% YoY at Rs 373 crore; Company Prepays Entire IREDA Term Loan
  • CPPIB to Invest ₹3,000 Crore in Prestige Estates' Hospitality Arm PHVL for Up to 28% Stake
  • Krystal Integrated Services Consortium Secures ₹740 Crore Urban Wastewater Contracts in Maharashtra

Keywords Selected:  Biosimilar

Stock Report

  • OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars
  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Lupin receives European Commission approval for Biosimilar Ranibizumab
  • Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
  • Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
  • EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
  • Ipca Laboratories Ltd enters into technology transfer agreement with Omexa Formulary Pvt Ltd
  • CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product
  • Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
  • CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
  • Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India
  • Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept

Latest Post

  • Lemon Tree Hotels signs Second hotel in Mcleodganj
  • Axis Mutual Fund launches Axis Nifty Energy Index Fund & Axis Nifty Energy ETF NFOs offering exposure to India's evolving capital energy ecosystem
  • Websol Energy Q1FY27 Revenue up 70% YoY at Rs 373 crore; Company Prepays Entire IREDA Term Loan
  • CPPIB to Invest ₹3,000 Crore in Prestige Estates' Hospitality Arm PHVL for Up to 28% Stake
  • Krystal Integrated Services Consortium Secures ₹740 Crore Urban Wastewater Contracts in Maharashtra


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025